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Abstract
Bacterial polysaccharides have numerous clinical or industrial uses. Recombinant plants could offer the possibility of
producing bacterial polysaccharides on a large scale and free of contaminating bacterial toxins and antigens. We
investigated the feasibility of this proposal by cloning and expressing the gene for the type 3 synthase (cps3S) of
Streptococcus pneumoniae in Nicotinia tabacum, using the pCambia2301 vector and Agrobacterium tumefaciens-mediated
gene transfer. In planta the recombinant synthase polymerised plant-derived UDP-glucose and UDP-glucuronic acid to form
type 3 polysaccharide. Expression of the cps3S gene was detected by RT-PCR and production of the pneumococcal
polysaccharide was detected in tobacco leaf extracts by double immunodiffusion, Western blotting and high-voltage paper
electrophoresis. Because it is used a component of anti-pneumococcal vaccines, the immunogenicity of the plant-derived
type 3 polysaccharide was tested. Mice immunised with extracts from recombinant plants were protected from challenge
with a lethal dose of pneumococci in a model of pneumonia and the immunised mice had significantly elevated levels of
serum anti-pneumococcal polysaccharide antibodies. This study provides the proof of the principle that bacterial
polysaccharide can be successfully synthesised in plants and that these recombinant polysaccharides could be used as
vaccines to protect against life-threatening infections.
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Introduction
Polysaccharide encapsulated bacteria are major causes of
disease and death in humans and animals. For example, diseases
caused by Streptococcus pneumoniae (the pneumococcus), Neisseria
meningitidis and Haemophilius influenzae are responsible for more than
two million deaths every year, the majority children under the age
of five [1,2][1,2]. Streptococcus pneumoniae alone is responsible for
more than 50 percent of invasive disease worldwide. Despite the
extensive use of pneumococcal vaccines, incidences of disease
caused by S. pneumoniae remain high, mainly due to serotypes not
included in the vaccine [3]. Current anti-pneumococcal vaccines
are composed of capsular polysaccharide alone or conjugated to
protein. Whatever the formulation, pneumococcal vaccine design
has to deal with the facts that there are over 90 different capsular
and the serotype distribution varies with time and geography.
However, for reasons of economics and biology the current
vaccines are limited in coverage (23 in the polysaccharide-only
vaccine and 13 in the new version of the conjugate) to the most
dominant serotypes in Europe and North America. Ideally
multiple versions of these vaccines are required and they would
be regularly reformulated to offer maximum protection. Cost of
polysaccharide production then becomes a concern. One of the
challenges for pneumococcal vaccine production is to manufacture
bacterial polysaccharide on a large-scale, without need for
purification procedures to remove contaminating toxins and
pyrogens. Currently the preparation of polysaccharides requires
expensive fermentation equipment, microbiological containment
and high levels of quality control to prevent contamination. Plants
offer a solution because they synthesise a large number of high
molecular weight polysaccharides, they have many of the sugar
precursors of bacterial capsular polysaccharide readily available
and plants have compartmentalised metabolic pathways and
transport processes that could facilitate polysaccharide extraction
[4]. However, until now heterologous antigen production in plants
has been limited to the production of proteins [5,6,7]. Here we
report that plants can be engineered to synthesise bacterial
polysaccharides and these polysaccharides provide protective
immunity. We demonstrated this principle using the serotype 3
capsular polysaccharide of S. pneumoniae, a serotype that is
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frequently isolated from disease cases. The type 3 polysaccharide is
composed of repeating D-glucose (Glc) and D-glucuronic acid
(GlcA) units, as (1R4)-b-D-Glcp-(1R3)-b-D-GlcpA-(1R4) [8,9]
The precursors, UDP-glucose (UDP-Glc) and UDP-glucuronic
acid (UDP-GlcA), are polymerised by a type 3 synthase (Cps3S)
[8,9].
Results
The Pneumococcal Type 3 Capsule Synthase Gene was
Cloned into Nicotinia tabacum by Agrobacterium-
mediated Gene Transfer
The pneumococcal cps3S gene {Dillard, 1995 #888} was
amplified from genomic DNA of the pneumococcal type 3 strain
WU2 using primers CPSFOR and CPSREV and cloned with
PR1b signal sequence (which was used to direct secretion of the
transgene to the apoplast) into the Agrobacterium binary vector
pCambia 2301, to give pCMS4. This placed cps3S under the
control of duplicated constitutive cauliflower mosaic virus
promoters, CaMV35S and also enabled selection of transformed
plants with kanamycin. Nucleotide sequence analysis of the cloned
cps3S in pCMS4 showed 100 % identity with the published
sequence [8].
Nicotiana tabacum was transformed with pCMS4 by A. tumefaciens-
mediated gene transfer. A T1 generation was grown from the
seeds of six plants and PCR showed that four plants contained the
1.3kb cps3S gene (Figure 1A). PCR also confirmed the absence of
contaminating Agrobacterium DNA (Figure 1B). RT-PCR, with
cps3S-specific primers, showed that the transgene was expressed in
the transgenic plants (Figure 2). No amplicon was generated by
direct PCR amplification of RNA extracts, confirming the absence
of contaminating cps3S DNA (Figure 2A). No amplicon was
generated by RT-PCR of untransformed plants (Figure 2A lane 3).
A second generation of plants were grown from the seeds of these
plants and PCR confirmed stable transgene expression (Figure S1).
All subsequent assays were done with second generation (T2) plant
material.
Pneumococcal Type 3 Polysaccharide was Detected in
the Leaves of Transformed Plants
Double immunodiffusion showed that type 3 antibody-antigen
complexes were seen (Figure 2B) between wells which contain
purified type 3 pneumococcal polysaccharide, sonicated plant cell
extract from transgenic plants (wells 1-4) and type 3 polysaccha-
ride specific antiserum (well A). This was not seen in wells
containing extract from a wildtype tobacco plants (wells 5 and 6).
Western blotting of transgenic and wildtype plant extracts using
type 3 polysaccharide specific antiserum also showed the presence
of type 3 polysaccahride in transgenic plant extracts only (Figure
2C). High-voltage paper electrophoresis of hot-acid hydrolysates of
cold-acid-extractable tobacco leaf polysaccharides confirmed these
findings (Figure 2D). Acid hydrolysis of polysaccharides from
transgenic leaves produced a relatively hot-acid-resistant, singly-
ionised disaccharide with the same mobility as the b-D-GlcpA-
(1R4)-D-Glc seen following acid hydrolysis of pneumococcal type
3 polysaccharide. This disaccharide was barely detectable in wild
type non-transformed plants (Figure 2D).
Immunisation with Transgenic Plant Extracts Protected
Mice from Pneumococcal Disease
To test the immunogenicity of the plant-derived type 3
polysaccharide, mice were immunised with three doses of apoplast
extracts from transgenic or wildtype plants. Sera were collected on
the day before each immunisation and ten days after the final dose,
and anti-type 3 polysaccharide IgG was determined by ELISA.
Significantly more (P,0.05) specific anti-type 3 antibody was
detected after a single dose of the transgenic leaf extract, with a
further increase (P,0.05) after a second dose (Figure 3A), whereas
antibody levels remained unchanged in those given wildtype
extracts (P.0.05).
Mice were challenged intranasally with the serotype 3 S.
pneumoniae strain HB565 230 days after the final immunisation.
Mice immunised with transgenic plant extract survived signifi-
cantly longer (P,0.001) than those given wildtype extracts (mean
survival: 181672h and 90623h for transgenic and wildtype,
respectively). Mice immunised with the wildtype extract did not
survive longer (P.0.05) than sham-immunised mice (91638h).
None of the fifteen animals given wildtype extract were alive ten
Figure 1. Detection of the cps3S gene in transformed tobacco plants. A. DNA was used as a template for PCR (Lanes 2, 3: wild type plants;
Lanes 4 – 7: transformed plants.) using cps3S-specific primers. PCR products were analysed by agarose gel electrophoresis. The results show the
presence of the cps3S gene in the transformed plants (Lanes 4 - 7) but not the wild type plants. The PCR reaction in Lane 9 contained purified plasmid
DNA containing cps3S (pCMS4) as a positive control and Lane 8 contained no template DNA. Molecular sizes are indicated. B. PCR showing the
absence of Agrobacterium DNA contaminating DNA preparations from wild type (Lanes 2, 3) and transformed (Lanes 4 - 7) tobacco plants. PCR was
done with Agrobacterium-specific primers. The results show that there was no Agrobacterium DNA present in the transgenic plant samples. The PCR
reaction in Lane 9 contained Agrobacterium DNA as a positive control and shows the expected 730bp band and Lane 8 contained no template.
Molecular sizes are indicated. DNA was extracted from the same six N. tabacum plants for the PCRs shown in A and B.
doi:10.1371/journal.pone.0088144.g001
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days after the challenge, whereas eight of the fourteen immunised
with transgenic extract survived (Figure 3B).
Discussion
This study has shown that bacterial polysaccharide vaccine
antigens can be synthesised in plants and that simple extracts of
these plants are immunogenic and protect against an otherwise
Figure 2. In planta expression of the cps3S gene and formation of serotype 3 polysaccharide. A. Reverse transcriptase PCR to detect cps3S
mRNA in transgenic tobacco plants. RNA was extracted from a wildtype (Lanes 1 and 3) and a transgenic N. tabacum containing cps3S (Lanes 2 and 4).
PCR products, using cps3S specific primers were analysed by agarose gel electrophoresis. Lanes 1 and 2 showed the absence of cps3S DNA in the
RNA. RT-PCR on the same samples showed the presence of cps3S mRNA in the transgenic plant (Lane 4) but not in the wildtype (Lane 3). Lane 5 PCR
of pCMS4 containing cps3S, done as before. The 1.3 kb amplicon in Lanes 4 and 5 shows a full-length transcript of cps3S is expressed in the transgenic
plant. B. Double immunodouble diffusion. Well 1:10 mg purified serotype 3 polysaccharide; Wells 2-4: extract from tobacco plants shown to express
cps3S: Wells 5 and 6: extract from a wildtype tobacco plant. Well A: type 3 polysaccharide specific antiserum. The preciptin lines identify the presence
of type 3 polysaccharide. C.Western blotting using type 3 polysaccharide specific antiserum. Lane 1: purified type 3 polysaccharide; Lane 2: wildtype
plant extract; Lane 3: transgenic plant extract. D. High-voltage paper electrophoresis of tobacco leaf acid hydrolysates. Lanes 1-3: 25 mg of each
marker, (Lane 1) galacturonic acid (GalA) and glucose, (Lane 2) glucose and b-D-glucuronosyl-(1R4)-D-glucose (GlcA–Glc) (partial hydrolysate of 10 mg
type 3 pneumococcal polysaccharide) and (Lane 3) 10 mg of a mixture of mannose, a-D-glucuronosyl-(1R2)-myo-inositol (GlcA–Ins) and a trace of a-D-
mannosyl-(1R4)-a-D-glucuronosyl-(1R2)-myo-inositol (Man–GlcA–Ins). Lanes 4–10: hydrolysate of polysaccharides cold-acid-extracted from 32 mg
fresh weight of wildtype (Lanes 4 and 5) or transgenic (Lanes 6–10) tobacco leaves. Each lane also contains a trace of Orange G (coloured internal
marker). All lanes show similar levels of staining for neutral sugars (co-migrating with glucose, near the origin). The samples were electrophoresed at
pH 6.5, at 3.0 kV for 60 min (anode at top) and stained with AgNO3. Spots of the disaccharide, GlcA–Glc, diagnostic of type 3 pneumococcal
polysaccharide, are highlighted by the dashed box; these spots were quantified for grey density in PhotoShop (see histogram).
doi:10.1371/journal.pone.0088144.g002
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lethal infection. Transgenic plants are recognised as good
expression systems for proteins but the synthesis of bacterial
polysaccharide in plants has not been demonstrated before.
We chose the production of the type 3 polysaccharide of S.
pneumoniae for the reason that it is a relatively simple carbohydrate,
being composed of repeating D-glucose (Glc) and D-glucuronic
acid (GlcA) organised as (1R4)-b-D-Glcp-(1R3)-b-D-GlcpA-(1R4)
units [8,9]. The precursors, UDP-glucose (UDP-Glc) and UDP-
glucuronic acid (UDP-GlcA) are naturally synthesised by plants,
which transport them into the endomembrane system as substrates
for cell wall polysaccharide synthesis [4,10]. Polymerisation of
these substrates into type 3 polysaccharide requires the enzyme,
type 3 synthase (Cps3S). Therefore, we cloned the pneumococcal
cps3S gene into N. tabacum using pCambia 2301. This strategy not
only placed cps3S under the control of duplicated constitutive
cauliflower mosaic virus promoters, CaMV35S, but it also enabled
selection of transformed plants with kanamycin. Growth of a
second generation of kanamycin-resistant plants confirmed stable
transgene expression. Although not the primary purpose of the
study, we did a limited investigation of how to extract the
pneumococcal polysaccharide from plant tissue. The method that
yielded the highest concentration of pneumococcal polysaccharide
was to grind the plant tissue under liquid nitrogen, suspend the
tissue in water and lyse the cells by sonication. Despite cloning the
signal sequence PR1b we detected no type 3 polysaccharide in its
destination, the apoplastic fluid. This implied that PR1b was not
functioning correctly. Previous studies replaced the start codon of
the transgene with PR1b [3], however, we maintained the start
codon and cloned an in-frame sequence of cps3S. This may have
led to a reduction in PR1b activity and improving this may
increase the yield of type 3 polysaccharide. Another method to
increase yield is to use root tissues, since the continuously growing
primary cell wall may contain higher concentrations of the UDP-
precursors. In this study we focussed on leaf tissue as we were
working with parent and F1 generations and removal of the roots
may have restricted growth of the plant and seed development.
Leaf tissue was also much easier to obtain. For these reasons, the
levels of polysaccharide extracted from plant tissue may not have
been optimal.
Having shown the principle of in planta synthesis using the linear
type 3 polysaccharide, the next challenge is the production of more
complex, branched, bacterial polysaccharides. All the genes
involved in pneumococcal capsular polysaccharide synthesis are
closely linked on the bacterial chromosome, arranged within a
single locus (a ‘‘type specific’’ cassette). Therefore, it is possible that
the introduction of whole cassettes could lead to the synthesis of
sugar precursors not naturally occurring in the plant and their
assembly into more complex polysaccharides. Furthermore,
effective signal or transport peptides should allow easier extraction
by compartmentalising different polysaccharides.
Because anti-polysaccharide antibodies are protective against
several bacterial pathogens of humans and animals there is great
interest in polysaccharides as vaccines. However, some of the
problems with these vaccines are illustrated by vaccines against S.
pneumoniae. The current pneumococcal vaccine contains twenty-
three polysaccharide serotypes but protection is serotype-specific
and some are not immunogenic in children. The vaccine was
formulated on the prevalence of serotypes in North America and
Europe, but elsewhere the coverage can be considerably less [11].
In addition to protection being serotype-specific, polysaccharide
immunogenicity also varies with serotype and age [12]. Further-
more, temporal variation occurs in the serotypes isolated from
adults and children [13]. Thus it has been suggested that different
vaccine formulations should be manufactured for differing
situations [14], but unless low-cost solutions are found it will not
become a reality. Polysaccharide vaccines can be expensive, which
restrains their use in developing countries. Production of
polysaccharide vaccines in plants can introduce economies of
scale that can drive down the production costs. The alternative, of
using microorganisms as the vaccine production system, requires
expensive fermentation equipment and high levels of quality
control to prevent contamination. In contrast, the use of plants for
vaccine production offers an achievable solution, opening the
possibility of local production, which increases the likelihood of
adoption of the vaccine [15].
Efforts to improve the poor immunogenicity of polysaccharide
vaccines in the young are focused on the development of
polysaccharides covalently linked to protein, but these make
difficulties with serotype coverage worse. When the US FDA
licensed a 7-valent anti-pneumococcal conjugate vaccine (Prevnar)
the serotypes covered by the vaccine caused 90% of disease in
North America and Europe, but less than 70% in Asia [15]. This
emphasises the desirability of a ‘tailor-made’ vaccine. However,
formulations of conjugates for a particular country or for
Figure 3. Immunogenicity and protective efficacy of serotype 3 pneumococcal polysaccharide produced in planta. A. Concentration of
serotype 3 polysaccharide-specific IgG in serum of mice immunised with extracts from tobacco plants expressing cps3S (black bars) or wildtype plant
(white bars); n = 5. B. Survival of mice challenged with virulent type 3 pneumococci 230 days after the final immunisation with transgenic plant
extract (closed triangles), wildtype extracts (open triangles) or sham-immunised mice (closed circles). Mice alive at 240h post-infection were
considered to have survived the infection.
doi:10.1371/journal.pone.0088144.g003
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childhood and for adult vaccination programmes are even less
likely than pure polysaccharide formulations, unless cheaper
production methods can be found. Conjugate vaccines are very
expensive and the pneumococcal conjugates will be more
expensive than any other current vaccine. Even with tiered
pricing the price of these vaccines is a real concern for their uptake
[16]. The ability to produce polysaccharide vaccines in plants, on
a large scale, could lead to a ready availability of polysaccharides
for protein conjugate vaccine production. There is, however, a
more exciting possibility, namely to exploit the plant’s glycosyl-
ation machinery to glycosylate heterologous proteins with heter-
ologous polysaccharide to make conjugate vaccines in planta. Plants
making heterologous immunogen represent an innovative tech-
nology for the development of childhood vaccines. The longer-
term objective of this research is to synthesise polysaccharide-
protein conjugates in plants.
In planta synthesis of bacterial polysaccharide and conjugates
offers an innovative contribution to vaccinology. Synthesising
heterologous polysaccharides in plants represents the first proof of
concept step in this process. These experiments have yielded
exciting data even though no attempt was made to optimise gene
expression, polysaccharide purification or immunising protocol.
These are developmental issues for the future now that the concept
that bacterial polysaccharide can be synthesised in plants has been
proven.
Materials and Methods
Construction of the Plant Expression Vector
The sequence of the type 3 pneumococcal capsular polysac-
charide biosynthesis cassette was obtained from GenBank (www.
ncbi.nlm.nih.gov), accession number U15171. A 1.3 kb DNA
fragment containing the cps3S gene was obtained by PCR from the
genomic DNA of S. pneumoniae serotype 3 (WU2) using the
oligonucleotide primers sense (CPSFOR) 59-CTG GTAQCCC
ATG TAT ACA TTT ATT TTA ATG TTG TTG G-39
corresponding to 2227bp - 2254bp with a KpnI restriction site
inserted at the 59 end; anti-sense (CPSREV) 59- TCA TCA CTC
TGT TAA ATT CCT AGT TCC -39, corresponding to 3454bp -
3479bp of the cassette. The PCR amplification was performed in a
total volume of 50 ml. using 2 mg genomic template under the
following conditions: 94uC for 4 minutes and then a cycling
procedure comprising denaturation at 94uC for 45 seconds,
annealing at 58uC for 1 minute, and extension at 72uC for 1
minute 30 seconds, which was repeated either 10 or 30 times, and
a final extension at 72uC for 10 minutes. Amplified DNA resulting
from PCR were purified from the PCR reagents using the
QIAquick PCR purification kit (Qiagen). The amplified fragment
was inserted into the multiple cloning site of pCR4-TOPO
(Invitrogen, Carlsbad, CA, USA). The Agrobacterium binary vector
pPZP221 (GenBank U10463) [17] has been previously engineered
to produce vector pCHF2 (Figure 4) containing the constitutively
expressed cauliflower mosaic virus (CaMV) 35S promoter and a
Figure 4. Construction of the pCMS4 vector. A. The digested products of three separate restriction digests of pCMS3 and pCambia 2301. Lane 1
shows the expected 3 fragments of pCMS3 when digested with EcoR I and Kpn I. Lane 2 shows the expected 2 fragments produced from the
digestion of pCMS3 with Kpn I and HinD III. Lane 3 shows the expected band of 11.5 Kbp when pCambia 2301 was digested with EcoR I and HinD III.
The DNA fragments of 864bp (Lane 1) and 1978bp (Lane 2), indicated by the arrows, were used to reconstruct the pCMS3 T-DNA fragment containing
cps3S and these were ligated to the 11.5 Kb pCambia fragment (Lane 3). This plasmid was termed pCMS4. Undigested DNA is not shown. A 1 Kb
ladder (New England Biolabs) was used as a molecular size marker. B. The expression vector pCHF2. A CaMV35S promoter, rbcS terminator region,
and a PR1B signal sequence were cloned into the T-DNA region of the pPZP222 vector [17]. The unique restriction endonuclease sites are also shown.
doi:10.1371/journal.pone.0088144.g004
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rbcS terminator (C. Fankhauser, personal communication). Here,
synthetic primers homologous to the PR1b signal peptide sequence
[18] were annealed, phosphorylated and inserted into pCHF2
using SacI and KpnI cutting sites situated between the CaMV 35S
promoter and the rbcS terminator. The cps3S gene was removed
from the pCR4-TOPO vector using KpnI and PstI and inserted
between the PR1b signal sequence and the rbcS terminator
sequence, to form the clone pCMS3. The entire expression
cassette was then excised from pCMS3 with EcoRI and HinDIII
and ligated into the binary plant vector pCAMBIA2301 (GenBank
accession number AF234316) (containing a kanamycin-resistance
gene and gus) to give the resulting plasmid, pCMS4.
Transformation of Plants
pCMS4 was introduced into Agrobacterium tumefaciens strain
GV3101 directly by the heat shock method, using 0.5 ml (1 mg)
pCMS4 and 0.1 ml of frozen CaCl2-competent A. tumefaciens cells.
Cells were thawed at 37uC for 5 minutes, re-suspended in 1 ml of
YEP broth (10 g/L Yeast Extract, 10 g/L Peptone, 5 g/L NaCl,
pH 7.0) and incubated at 28uC for 2 hours with gentle shaking.
Cells were harvested by centrifugation at 600 g for 10 minutes, the
pellet re-suspended in 0.1 ml YEP and spread onto YEP agar
containing 100 mg/ml kanamycin and 100 mg/ml rifampicin and
incubated overnight at 28uC. Subsequently, A. tumefaciens carrying
pCMS4 was used to transform tobacco (Nicotiana tabacum cv SR1)
leaf discs, as described previously [19]. Leaf discs were then
transferred to Murashige-Skoog (MS) agar containing 3% (w/v)
sucrose, the plate was sealed with parafilm and incubated in the
dark at room temperature for 2 days. Discs were then transferred
to selective medium (MS agar containing 3% (w/v) sucrose,
250 mg/ml cefotaxime (to kill the A. tumefaciens on the surface of
explants), 100 mg/ml kanamycin, 100 mg/ml ampicillin, 100 mg/
ml naphthalene acetic acid (NAA) and 1 mg/ml 6-benzylamino-
purine) to select transgenic progeny. Ten days post-infection, those
discs showing shoot formation were transferred to fresh selective
medium and re-incubated for approximately 1-2 weeks. Larger
shoots were transferred to powder rounds containing the same
medium and incubated for a further 3 weeks, or until roots started
to form. After eight weeks, kanamycin-resistant shoot regenerants
were removed to a rooting medium containing 100 mg/ml NAA
and 25 mg/ml kanamycin. Rooted plantlets were transferred to
soil, self-pollinated and the seeds stored desiccated at 4uC.
Detection of cps3S Gene Expression in Transgenic Plants
Total RNA was isolated from 100 mg of leaf tissue using a RNA
isolation kit (RNeasy Plant Mini Kit; Qiagen, Surrey, UK) and
used in the production of first strand cDNA using a cDNA
synthesis kit (RNase H2 reverse transcriptase kit; Invitrogen) and a
random hexa-nucleotide primer. PCR was then performed using
the CPSFOR and CPSREV primers as described above, RNA
extracts without prior reverse transcriptase treatment were used as
a control to indicate the presence of cps3S specific DNA. RNA
extracted from wild-type tobacco leaves also was used as negative
control. To confirm the absence of contaminating Agrobacterium
DNA PCR was done with the primers VCF (59-ATC ATT TGT
AGC GAC T-39) and VCR (59-AGC TCA AAC CTG CTT C-
39), designed to amplify a 730bp region of the virC gene of
Agrobacterial Ti and Ri plasmids [20].
Preparation of Leaf Extracts
Leaves were collected from tobacco plants, tissue ground under
liquid nitrogen and nanopure water added to give 0.5 g/ml plant
tissue. The cells were lysed by sonication: 6630 second sonications
at an amplitude of 50 microns with 30 second rests in between
sonications. The cell lysate then was centrifuged for 5 minutes at
10,000 g and the supernatant divided into 1 ml volumes,
lyophilised and stored at 4uC.
Extraction of type 3 Polysaccharide from Apoplastic Fluid
A modification of the method described by Fry and co-workers
was used [21]. Leaf material (1 g) was added to 50 ml of 50 mM
CaCl2 and vacuum-infiltrated for a period of 30 minutes. The
leaves were removed and dried gently on a paper towel before
being transferred to the barrel of a 25 ml syringe with the plunger
removed. This was placed in a 50 ml Falcon tube and the
assembly centrifuged at 800 g at 10uC for 10 minutes. The
aqueous extract was stored at 4uC until required.
Double Immunodiffusion
A modification Ouchterlony’s method was used [22]. 0.2% (w/
v) Ouchterlony agarose in barbitone buffer (1.84 g/l diethylbarbi-
turic acid, 10.3 g/l sodium diethylbarbiturate, pH 8.6) was used to
coat microscope slides. These were left to dry for 1 hour, and then
overlaid with 4.5 ml 1% (w/v) agarose in barbitone buffer. Once
set, 4 mm holes were cut and 20 ml of sample was placed in the
outer holes. Type 3 polysaccharide from S. pneumoniae (ATCC),
diluted in 20 ml of untransformed plant extract, was used as a
positive control. The central hole contained 20 ml neat rabbit anti-
type 3 polysaccharide antiserum (Statens Serum Institute,
Copenhagen, Denmark). The slides were incubated at 4uC in a
humidity box for 1-2 weeks. Precipitin lines were observed and
photographed in indirect light. Recombinant pneumococcal
polysaccharides were estimated by comparison with the intensity
of the precipitin lines of the positive controls.
High-Voltage Paper Electrophoresis (HVPE)
Leaf material was harvested, washed, cut into pieces and ground
into a fine powder under liquid nitrogen. Samples were stored at –
20uC until required. To 10 g fresh weight was added 50 ml 5%
(v/v) formic acid and the suspension was incubated with gentle
shaking for 2 days at room temperature. This procedure is
expected to extract the capsular polysaccharide, but only a small
proportion of the leaf cell-wall polysaccharides and starch. The
homogenate was filtered through Miracloth and rinsed with 25 ml
water and then the combined filtrate was adjusted to pH 4.0 with
pyridine. Co-extracted proteins were denatured at 100uC for 60
min, then cooled and pelleted by centrifugation at 17006g for 15
min; the supernatant was freeze-dried. The dried material was
washed exhaustively at room temperature in several changes of
82.6% (v/v) ethanol, which dissolves low-MW sugars. The
remaining insoluble, polysaccharide-rich material was then air-
dried, incubated at 90uC for 30 min in 22.6 ml water and cooled;
trifluoroacetic acid (TFA) was then added to a final concentration
of 0.36 M, which solubilised the polysaccharide.
For partial hydrolysis of the polysaccharide to yield the
relatively acid-resistant, diagnostic dimer (aldobiouronic acid;
GlcA–Glc) a portion of the solution was hydrolysed in 2 M TFA at
120uC for 30 min [conditions optimised in preliminary runs with
authentic type 3 polysaccharide; data not shown], then dried in
vacuo. The hydrolysis products were redissolved in water contain-
ing a trace of Orange G (internal anionic marker), and a volume
(equivalent to 32 mg fresh weight of leaf) was spotted on to
Whatman 3 MM paper. The samples were subjected to HVPE at
pH 6.5, at 3.0 kV for 60 min [23] and then stained with silver
nitrate [21] to reveal sugars. External markers, run on the same
sheet, included hydrolysates of (i) purified Type 3 polysaccharide
(yielding glucose plus GlcA–Glc), and (ii) the trimer a-D-mannosyl-
(1R4)-a-D-glucuronosyl-(1R2)-myo-inositol [24] (which yields a
Novel Bacterial Polysaccharide Vaccine Production
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comparable dimer, a-D-glucuronosyl-(1R2)-myo-inositol, plus
mannose). Other markers were commercial glucose and galac-
turonic acid. After staining with silver nitrate [21], electropho-
retograms were scanned and relevant spots were quantified for
grey density in PhotoShop, as described in Supplementary Figure
1 of Parsons et al [25].
Immunisation and Challenge
Nine-week-old MF1 female mice (HarlanOlac, Bicester, UK)
were given three doses of control plant extract or plant extract
containing 2 mg plant-derived pneumococcal polysaccharide per
mouse (as estimated by the Ouchterlony method) in 67 ml PBS and
33 ml Imject alum adjuvant (Pierce, Rockford, IL, USA). Mice
were immunised intraperitoneally on days 0, 10, 20 and 30. Sham-
immunised mice received alum adjuvant containing an irrelevant
immunogen (KLH) using the same schedule. Serum samples were
obtained by tail bleeding the day before each immunisation. Mice
were challenged intraperitoneally with 2.86106 cfu serotype 3
pneumococci on Day 260. The health status of animals was
monitored, according to the scheme of Morton et al [26].These
experiments were done under a project licence from the UK
Home Office.
ELISA
Maxisorb ELISA wells (Gibco BRL, Nunc products) were
coated with 2 mg/ml purified type 3 pneumococcal polysaccharide
(ATCC) in coating buffer (50 nM NaHCO3 pH 9.6, 0.02% (w/v)
NaN3) for 16 h at 22uC. After rinsing with PBS, the wells were
blocked with PBS + 5% (w/v) dried milk at 37uC for 1 h and
washed three times with washing buffer (50 mM TrisHCl pH 7.5,
150 mM NaCl, 0.05% (v/v) Tween20). Mouse sera were diluted
1:100 in blocking buffer and 100 ml added to the wells and
incubated, shaking, for 2 hours at 37uC. The plates were washed
three times as before and bound antibodies were detected using
alkaline phosphatase-conjugated goat anti-mouse IgG secondary
antibody (Fc specific, Sigma; diluted 1:5000), and 1 mg/ml p-
nitrophenyl phosphate (Sigma) dissolved in 1 M diethanolamine
pH 9.8, 0.5 M MgCl2. Absorbance was read at 405 nm after 1
hour at 37uC and IgG concentration determined by reference to a
standard curve prepared with murine IgG (Statens Serum
Institute).
Western blot analysis
Western blotting was performed on leaf extracts as described
previously [27].
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5
(GraphPad, San Diego, CA, USA). The differences in antibody
titres from mice immunised with transgenic or wildtype plant
extracts were analysed using a student’s T-test. Survival data were
analysed by the Kaplan-Meier survival curve analysis.
Supporting Information
Figure S1 Confirmation of the stable transformation of
tobacco plants with the cps3S gene. Plant RNA was used as
a template for reverse transcriptase PCR (RT-PCR) (Lane 1: wild
type plants; Lane 2: transformed plants.) using cps3S-specific
primers. RT-PCR products were analysed by agarose gel
electrophoresis. The results show the presence of the cps3S gene
in the transformed plants (Lane 2) but not the wild type plants.
(DOCX)
Acknowledgments
We would like to acknowledge the contribution of Professor Whitelam who
died during the production of this manuscript. We thank William. S.
Hawes for his technical contribution and help with plant transformation.
SCF thanks the UK Biotechnology and Biological Sciences Research
Council for support.
Author Contributions
Conceived and designed the experiments: CMS SCF KCG ISR PWA
GCW. Performed the experiments: CMS SCF AJFP SG MG ISR PWA.
Analyzed the data: CMS SCF AJFP SG ISR. Contributed reagents/
materials/analysis tools: SCF KCG ISR PWA. Wrote the paper: CMS
SCF ISR PWA.
References
1. Gilbert C, Robinson K, LePage RWE, Wells J (2000) Heterologous expression of
an immunogenic pneumococcal type 3 capsular polysaccharide in Lactococcus
lactis. Infect Immun 68: 3251–3260.
2. Deuren M, Brandtzaeg P, van der Meer JW (2000) Update on meningococcal
disease with emphasis on pathogenesis and clinical management. Clin Microbiol
Rev 13: 144–166.
3. CDC (2005) Direct and indirect effects of routine vaccination of children with 7-
valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal
disease—United States, 1998–2003. 54: 893–897.
4. Kunze R, Frommer WB, Flugge UI (2002) Metabolic engineering of plants: the
role of membrane transport. Metab Eng 4: 57–66.
5. Gao Y, Ma Y, Li M, Cheng T, Li SW, et al. (2003) Oral immunization of
animals with transgenic cherry tomatillo expressing HBsAg. World J Gastro-
enterol 9: 996–1002.
6. Mason HS, Arntzen CJ (1995) Transgenic plants as vaccine production systems.
Trends Biotechnol 13: 388–392.
7. Rigano MM, Alvarez ML, Pinkhasov J, Jin Y, Sala F, et al. (2004) Production of
a fusion protein consisting of the enterotoxigenic Escherichia coli heat-labile
toxin B subunit and a tuberculosis antigen in Arabidopsis thaliana. Plant Cell Rep.
22: 502–508.
8. Arrecubieta C, Garcia E, Lopez R (1996) Demonstration of UDP-glucose
dehydrogenase activity in cell extracts of Escherichia coli expressing the
pneumococcal cap3A gene required for the synthesis of type 3 capsular
polysaccharide. J Bacteriol 178: 2971–2974.
9. Jennings H (1983) Capsular polysaccharides as human vaccine. Adv Carbo
Chem 41: 155–208.
10. Sharples SC, Fry SC (2007) Radioisotope ratios discriminate between competing
pathways of cell wall polysaccharide and RNA biosynthesis in living plant cells.
Plant J. 52: 252–262.
11. Kalin M (1998) Pneumococcal serotypes and their clinical relevance. Thorax 53:
159–162.
12. Douglas RM, Paton JC, Duncan SJ, Hansman DJ (1983) Antibody response to
pneumococcal vaccination in children younger than five years of age. J. Infect.
Dis. 148: 131–137.
13. Imo¨hl M, Reinert RR, van der Linden M (2010) Temporal variations among
Invasive pneumococcal disease serotypes in children and adults in Germany
(1992–2008). Internat J Microbiol 2010: 1–15.
14. Snaidack DH, Schwartz B, Lipman H, Bogaets J, Butler JC, et al. (1995)
Potential interventions for the prevention of childhood pneumonia: geographic
and temporal differences in serotype and serogroup distribution of sterile site
pneumococcal isolates from children. Pediatr. Infect. Dis. J. 14: 503–509.
15. Hausdorff WP, Bryant J, Paradiso PR, Siber GR (2000) Which pneumococcal
serotypes cause the most invasive disease: implications for conjugate vaccine
formulation and use. Clin Infect Dis 30: 100–121.
16. Levine MM, Levine OS (1997) Influence of disease burden, public perception
and other factors on new vaccine development, implementation and continued
use. Lancet 350: 1386–1392.
17. Hajdukiewicz P, Svab Z, Maliga P (1994) The small, versatile pPZP family of
Agrobacterium binary vectors for plant transformation. Plant Molec Biol 25:
989–994.
18. Lund P, Dunsmuir P (1992) A plant signal sequence enhances the secretion of
bacterial ChiA in transgenic tobacco. Plant Mol Biol 18: 47–53.
19. Draper J, Scott R, Armitage P, Walden R (1988) Plant genetic transformation
and gene expression: a laboratory manual. Oxford, Blackwell Scientific
Publications.
20. Sawada H, Ieki H, Matsuda I (1995) PCR detection of Ti and Ri plasmids from
phytopathogenic Agrobacterium strains. Appl Environ Microbiol 61: 828–831.
Novel Bacterial Polysaccharide Vaccine Production
PLOS ONE | www.plosone.org 7 February 2014 | Volume 9 | Issue 2 | e88144
21. Fry SC (1988). The Growing Plant Cell Wall: Chemical and Metabolic Analysis.
New York, John Wiley and Sons.
22. Ouchterlony O, Nilsson,L (1973) Immunodiffusion and immunoelectrophoresis.
Oxford, Blackwell Scientific Publications.
23. Fry SC (2011). High-voltage paper electrophoresis (HVPE) of cell-wall building
blocks and their metabolic precursors (Springer, New York, High-voltage paper
electrophoresis (HVPE) of cell-wall building blocks and their metabolic
precursors. The Plant Cell Wall Methods and Protocols. Z. Popper. New York,
Springer: 55–80.
24. Smith CK, Hewage CM, Fry SC, Sadler IH (1999) 6-d-Mannopyranosyl-(1-.
4)-6-d-glucuronopyranosyl-(1-.2)-myo-inositol, a new and unusual oligosac-
charide from cultured rose cells. Phytochem 52: 387–396.
25. Parsons HT, Yasmin T, Fry SC (2011) Alternative pathways of dehydroascorbic
acid degradation in vitro and in plant cell cultures: novel insights into vitamin C
catabolism. Biochem J 440: 375–383.
26. Morton DB, Griffiths PH (1985) Guidelines on the recognition of pain, distress
and discomfortin experimental animals and an hypothesis for assessment Vet
Record 116: 431–436.
27. McNulty C, Thompson J, Barrett B, Lord L, Andersen C, et al (2006) The cell
surface expression of group 2 capsular polysaccharides in Escherichia coli: the role
of KpsD, RhsA and a multi-protein complex at the pole of the cell. Mol.
Microbiol. 59: 907–922.
Novel Bacterial Polysaccharide Vaccine Production
PLOS ONE | www.plosone.org 8 February 2014 | Volume 9 | Issue 2 | e88144
